Full-Time

Quality Engineer

Systems & Compliance

Cogstate

Cogstate

201-500 employees

Digital cognitive assessments for brain health

Compensation Overview

$95k - $105k/yr

+ 401(k) Matching

Remote in USA

Remote

Category
QA & Testing (1)
Requirements
  • Bachelor's Degree in Science, Engineering, Information Technology, or equivalent field. Advanced degree preferred.
  • Minimum 5-8 years of experience in quality assurance within a regulated clinical trials, pharmaceutical, or medical device/SaMD environment.
  • Demonstrated hands-on experience with GxP system validation using GAMP 5 (2nd ed., 2022) and/or FDA Computer Software Assurance (CSA) guidance, including IQ/OQ/PQ and UAT for COTS, TPS, and eQMS platforms.
  • Direct experience qualifying vendors and third-party systems: developing qualification plans, executing audits, issuing reports, and managing CAPAs to closure.
  • Experience administering eQMS platforms (Qualio, Greenlight Guru, Veeva Vault QMS, MasterControl, or equivalent), including workflow configuration and quality event management.
  • Familiarity with TGA, MHRA, EMA, or other international regulatory authority inspection programs.
  • Experience supporting FDA QMSR or ISO 13485 third-party certification audits.
  • Experience with eTMF system qualification and clinical trial data management systems.
  • Experience planning and executing internal audit programs and supporting sponsor or regulatory authority audits and inspections.
  • Experience with 21 CFR Part 11 and/or EU GMP Annex 11 electronic records and signature requirements.
  • Demonstrated history of working independently with minimal oversight in a cross-functional environment.
  • GAMP 5 (2nd ed., 2022) and FDA Computer Software Assurance (CSA): risk-based validation methodology for COTS, configured, and custom GxP software.
  • 21 CFR Part 11 and EU GMP Annex 11: electronic records, audit trails, access controls, and e-signature compliance.
  • QMSR (21 CFR Part 820, as amended), ISO 13485:2016, ICH E6(R3), and ISO 14971:2019.
  • eQMS platform administration: quality event workflows (CAPA, NCR, deviation, change control, document management) in Qualio, Greenlight Guru, Veeva Vault QMS, MasterControl, or equivalent.
  • Vendor and TPS qualification: audit planning, execution, reporting, and CAPA management.
  • Internal audit methodology consistent with ISO 19011:2018.
  • ALCOA+ data integrity principles applied to electronic records and GxP documentation.
Responsibilities
  • Lead GxP system qualification and validation activities for the eQMS, COTS, and TPS using a risk-based approach aligned with GAMP 5 (2nd ed., 2022) and FDA Computer Software Assurance (CSA) guidance, covering the full validation lifecycle including IQ/OQ/PQ and UAT.
  • Develop, execute, and maintain system validation plans, validation reports, UAT scripts, requirements traceability matrices (RTMs), and periodic review records; ensure documentation satisfies 21 CFR Part 11 (US) and EU GMP Annex 11 (EU) electronic records requirements.
  • Administer and continuously improve eQMS quality event workflows - CAPA, nonconformance records (NCR), deviations, change controls, and document management — across eQMS platform.
  • Lead and maintain the Vendor Qualification Program and Third-Party System (TPS) audit schedule, including initial qualification, periodic requalification, performance monitoring, and maintenance of the approved vendor/TPS list in alignment with ICH E6(R3), ISO 13485/ISO 9001/ISO 27001 supplier control requirements, and other applicable requirements.
  • Lead vendor qualification and audit activities end-to-end: scope definition, audit plan development, execution (on-site or remote), report issuance, and CAPA follow-up through to verified closure.
  • Apply ALCOA+ data integrity principles across all system records, validation documentation, and QMS content; ensure eQMS configurations enforce audit trail, access controls, and data integrity requirements per 21 CFR Part 11 and Annex 11.
  • Manage system change controls, post-change impact assessments, and revalidation activities; maintain validated state inventory and support system periodic review cycles.
  • Identify and escalate GxP system compliance risks; lead root cause analysis and drive CAPA for system-related quality events, deviations, and audit findings.
  • Collaborate with IT and DevOps/QC on software release validation, infrastructure qualification, and integration testing in regulated environments.
  • Plan, execute, report, and manage follow-up on the internal audit program per established schedule, applying a risk-based methodology consistent with ISO 19011:2018; maintain inspection readiness per FDA Compliance Program 7382.850.
  • Own and maintain the vendor and TPS audit schedule; lead vendor audits, remote desktop reviews, and surveillance assessments; issue audit reports and manage findings through to closure.
  • Support sponsor audits and regulatory authority inspections: coordinate readiness activities across functions, facilitate audit hosting, assist with evidence preparation and retrieval, draft audit responses and CAPA plans, and track finding closure through effectiveness verification.
  • Track and trend audit findings, CAPA metrics, and systemic quality issues across the internal and vendor audit programs; report findings and quality metrics to the Manager, RAQA.
  • Coordinate system-related and QA training activities within Cogstate, including maintaining role-based training requirements for validated systems in the LMS, assigning training following system changes or CAPA closures, and supporting role-specific competency evidence as required.
Desired Qualifications
  • Ability to train and coach cross-functional teams on GxP system compliance, ALCOA+, and audit readiness.
  • Experience applying process improvement methodologies (Lean, Six Sigma, or equivalent) to QMS and validation workflows.
  • Familiarity with risk-based regulatory inspection frameworks and evolving FDA QMSR enforcement priorities

Cogstate provides digital cognitive assessments to support brain health research and drug development. Its tests are web- or app-based cognitive tasks that patients or trial participants complete, producing standardized scores that researchers can compare against validated benchmarks. Data from the tests is used in biopharma, academia, and clinical settings to measure cognition in trials and care, with accompanying consulting services. Unlike some competitors, Cogstate combines a long history (founded in 1999) with a focused application on cognitive measurement for pharmaceutical clinical trials and mental health/neurological conditions, along with ongoing scientific validation. The company’s goal is to improve the efficiency and reliability of cognitive measurement in research and clinical care to help develop and assess therapies for disorders like depression, schizophrenia, and bipolar disorder.

Company Size

201-500

Company Stage

IPO

Headquarters

Australia

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Medidata partnership integrates Cogstate into AI-powered clinical trial platform ecosystem.
  • Expanding mood disorder and neurodegenerative disease focus captures high-value biopharma segments.
  • $82M revenue base with 160 employees demonstrates operational efficiency and scalability.

What critics are saying

  • AI-native competitors (Clinion, Signant) offer integrated eCOA platforms undercutting standalone tests.
  • FDA's 2025 decentralized trial mandate requires real-time AI analytics Cogstate lacks.
  • Open-source DeepMind cognitive models enable biopharma to bypass proprietary assessments entirely.

What makes Cogstate unique

  • 25-year track record in cognitive assessment with 220 clinicians across 40+ languages.
  • Proven profitability: 11% annual EPS growth, EBIT margins expanded 14% to 25%.
  • Strategic hires (Dr. Sink, Dr. Lucić) strengthen Alzheimer's and psychiatry trial leadership.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Cogstate who can refer or advise you

Benefits

Remote Work Options

Generous Paid Time-off

401(k) Matching

Health, Dental & Vision Coverage

Short-Term & Long Term Disability Life Insurance

Pre-Tax Benefits

Learning & Development Opportunities

Company News

Yahoo Finance
Jan 19th, 2026
Cogstate grows EPS 11% annually as EBIT margins expand from 14% to 25%

Cogstate, an ASX-listed technology company, has attracted investor attention due to its profitability and growth trajectory. Over the past three years, the company has grown earnings per share by 11% annually, whilst EBIT margins improved from 14% to 25% alongside revenue growth. The company's performance stands in contrast to loss-making speculative investments, offering a more traditional investment opportunity based on proven profitability. Cogstate's financial sustainability and consistent earnings growth demonstrate its ability to generate returns without the heightened risks associated with pre-revenue companies. Investors are also monitoring insider activity, as insider buying often signals confidence in future share price performance, though this indicator alone does not guarantee success.

Cogstate
Aug 18th, 2025
Cogstate Bolsters Mood Disorder Expertise, Welcoming Dr. Luka Lucić as Senior Director of Clinical Science in Psychiatry

New Haven, CT - August 18, 2025 - Cogstate, a leading neuroscience technology company, today announced the appointment of Luka Lucić, PhD, as Senior Director, Clinical Science, Psychiatry.

Business Wire
Oct 29th, 2024
Medidata and Cogstate Strike Strategic Partnership Transforming Clinical Trials in Neurology with Clinical Outcome Assessment (eCOA) and Clinician Solutions Powered by AI and Advanced Analytics

Science-driven collaboration ameliorates neurological assessments and endpoint data quality, enhances the rater and patient experience, and integrates Medidata App innovations with Cogstate capabilities

GlobeNewswire
Oct 14th, 2024
Cogstate Expands Alzheimer'S Disease Leadership With Appointment Of Dr. Kaycee Sink, As Chief Medical Officer

Melbourne, VIC, Australia; New Haven, CT, USA, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Cogstate, a leading neuroscience technology company, today announced the appointment of Kaycee Sink, MD, MAS, as Chief Medical Officer. In this role, Dr. Sink will lead Cogstate’s support of clinical trials in Alzheimer’s disease and other neurodegenerative disorders, including the advancement of new innovations to improve data quality and trial efficiency for more accurate conclusive studies. Dr. Sink will use her extensive experience in Alzheimer’s disease drug development—gained from leading global trials and programs—to advise biopharmaceutical leaders through strategic trial design decisions, endpoint selection, and data quality considerations for cognitive and clinical outcome assessments

TipRanks
Apr 4th, 2024
Cogstate Continues Share Buy-Back Initiative

Cogstate Ltd has announced an update to their on-market share buy-back program, reporting the purchase of 9,787 shares on the previous day, adding to a total of 92,203 shares bought back to date.